Dacarbazine mediate antimelanoma effects via NK cells. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue OncoImmunology Année : 2013

Dacarbazine mediate antimelanoma effects via NK cells.

Résumé

Melanoma is a highly chemoresistant and metastatic tumor that, in the absence of BRAF mutations, is generally treated with the alkylating agent dacarbazine (DTIC). We discovered that DTIC upregulates the expression of NKG2D ligands on tumor cells, leading to the activation of natural killer (NK) and CD8(+) T cells. These observations underscore the immunogenic properties of DTIC and provide a rationale to combine DTIC with immunotherapeutic agents.

Domaines

Immunologie
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée
Loading...

Dates et versions

inserm-00857884 , version 1 (04-09-2013)

Identifiants

Citer

Alice Hervieu, Gregoire Mignot, François Ghiringhelli. Dacarbazine mediate antimelanoma effects via NK cells.. OncoImmunology, 2013, 2 (4), pp.e23714. ⟨10.4161/onci.23714⟩. ⟨inserm-00857884⟩
132 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More